FY27 revenue broadly flat
Full-year revenue expected to be broadly flat vs FY26, with H2 meaningfully stronger than H1.
SYNGENEINTERNATIONAL / guidance tracker
Keep management guidance in view.
Syngene International · forward-looking guidance across the available source record.
Research layer active
Guidance tracker
What management said would happen.
revenue
FY27 EBITDA margin in mid-20s
EBITDA margin guided to mid-20% range through disciplined cost management.
Librella revenue minimal in H1 FY27
Librella revenue expected to be near zero in Q1 and Q2, with minor volumes in Q4.
Bay View biologics facility operational in FY27
Preparations progressing; engineering batches expected in FY27 with regulatory approvals to follow.